FDA allows use of Genentech's Rituxan for 2 orphan diseases - Related Stories - AHIP Solutions SmartBrief
Links shared publicly online about this topic.
- 351total visits
FDA allows use of Genentech's Rituxan for 2 orphan diseases - Related Stories - AHIP Solutions SmartBrief
The FDA authorized Genentech to promote blockbuster drug Rituxan as a treatment for Wegener's granulomatosis and microscopic polyangiitis, which are rare vasculitis-causing disorders. Rituxan is already used in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthri--
View full resource at smartbrief.com
Tags: Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Disease and Condition, Drug, FDA, Rituxan, Genentech, disease
Most Recently Shared on April 20, 2011 at 3:33 pm By:
FDA allows use of Genentech's Rituxan for 2 orphan diseases http://sbne.ws/r/7iOF
Advertisement
